Ongoing HTAs of in-vitro diagnostic tests in Norway

07

Jun 2021

In 2013, Norway established a framework for the introduction of innovations into the health care system through either a national or hospital-based health technology assessment. This framework is called the “New Method”.

In this framework, all innovations should undergo HTA before being funded. If the method concerns only one or two hospitals, the assessment shall be initiated by clinicians and ran at the hospital level. The final report is disseminated via a mini-HTA database. If the method is of national concern, it undergoes Single Technology Appraisal at the national level, followed by the funding decision by the group of payers (Decision Forum, Beslutningsforum).

As of June 7, 2021, five HTAs of in-vitro diagnostics are launched in a framework of the New Method process:

  • Histotyping (AI that makes predictions about cancer patients by directly analyzing digitally scanned histological sections of the tumor) (link);
  • Diagnostic tests for further cancer treatment;
  • Programmed Death Ligand 1 expression test in tumor tissue samples;
  • RET gene changes test in thyroid cancer and non-small cell lung cancer;
  • Preeclampsia screening algorithm.

The full list can be seen here in Norwegian. 

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First, EU issues of both newsletters are available for download free-of-charge.

The latest related news

22

Jun 2021

In late May 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0177 and 0074 with changes to be implemented not later than August 01, 2021. Five new procedure codes related to diagnostic imaging, ENT, breast reconstruction, and gynecology, and nine new diagnostic codes were introduced.

Read more

21

Jun 2021

On June 16, 2021, the Institute for Quality and Efficiency in Health Care (IQWiG) has opened the submission period for proposals for topics of the health technology assessment (HTA) reports to be developed in 2022.

Read more

18

Jun 2021

In May 2021, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (ex-situ machine perfusion for extracorporeal preservation of lungs for transplant, transvaginal laser therapy for stress urinary incontinence and for urogenital atrophy, electrohydraulic lithotripsy for difficult-to-treat bile duct stones, and permanent His-bundle pacemaker for heart failure), one new Medical Technologies Guidance (UroLift for benign prostatic hyperplasia), and two new Medtech Innovation Briefings (Axonics sacral neuromodulation system for faecal incontinence and KODEX-EPD for cardiac imaging during ablation of arrhythmias). Also, three clinical guidelines and two Medical Technologies Guidance were updated.

Read more

17

Jun 2021

In late May 2021, the Treatment Council (Behandlingsråd), a new framework for assessing treatments and health technologies in Denmark, started accepting applications for the assessment of health technologies.

Read more

16

Jun 2021

The Health Sciences Institute in Aragon (IACS) systematically evaluates healthcare technologies and facilitates the promotion of research, effective innovation, and decision-making in health services through knowledge management. Currently, the IACS is working on assessments of efficacy, effectiveness, and safety of intraoperative radiation therapy in breast cancer, determination of preeclampsia biomarkers SFlt-1 and PlGF, treatment of congenital ventricular septal defect by cardiac catheterization, and others.

Read more